TLDR
- POAI stock surges 83% with bold $344M crypto-linked treasury strategy.
- Predictive Oncology enters digital asset space with ATH-powered treasury.
- POAI unveils $344M funding deal to anchor new ATH token-based treasury.
- ATH token deal drives POAI stock up 83% in speculative buying frenzy.
- Digital asset push fuels POAI stock rally as it partners with Aethir.
POAI stock surged 83.85% today, trading at $1.4250 after an early morning spike above $4. The company confirmed the pricing of two private placement transactions worth $344.4 million. This development marked the official launch of its digital asset treasury strategy centered on ATH, the native token of Aethir.
Predictive Oncology Inc. (Nasdaq: POAI)
Private Placement Transactions
The company structured two private placements to support its strategic move into digital assets. The cash-based placement raised approximately $51.7 million through the sale of 66.7 million shares at $0.7751 each. The second placement involved pre-funded warrants linked to ATH tokens valued at roughly $292.7 million.
Both placements are expected to close on October 2, 2025, following customary conditions. The cash placement provided direct funding, while the crypto placement introduced significant in-kind contributions of ATH tokens. This dual approach emphasized the company’s intention to secure immediate capital while gaining exposure to the growth of digital infrastructure.
The company confirmed that the warrants from the crypto placement would become exercisable after shareholder approval. This structure allowed flexibility while aligning the treasury expansion with governance requirements. The move also laid the groundwork for the digital asset treasury strategy to scale even further.
Adoption of ATH and Strategic Treasury Plan
Predictive Oncology outlined its plan to integrate ATH into its balance sheet through market purchases and in-kind contributions. The company will allocate net proceeds to acquire ATH tokens from exchanges to reinforce its treasury holdings. In addition, the DCI Foundation agreed to provide a 20% ATH token bonus for every market purchase.
Aethir operates one of the largest decentralized GPU networks, spanning 200 locations across 93 countries. Its infrastructure offers rapid deployment of compute resources, creating cost advantages compared to traditional providers. By holding ATH, Predictive Oncology gains operational participation in this ecosystem.
The digital asset treasury strategy positions the company to establish a Strategic Compute Reserve. This reserve aims to strengthen Aethir’s deployment capacity while expanding Predictive Oncology’s business scope. The integration also signals a long-term commitment to AI infrastructure and tokenized compute economics.
Advisors and Legal Framework
The company appointed DNA Holdings Venture Inc. as its strategic advisor and consultant. H.C. Wainwright & Co. acted as exclusive placement agent, while DLA Piper LLP provided legal counsel to the company. Sheppard Mullin Richter & Hampton LLP served as counsel to DNA Holdings Venture Inc.
The securities were issued under exemptions from the Securities Act of 1933, with resale subject to registration. Predictive Oncology also signed registration rights agreements to ensure compliance with federal securities laws. This framework secures legal certainty for both equity and digital asset components.
Stockholders recently approved a one-for-fifteen reverse stock split effective September 30, 2025. This action streamlined the company’s capital structure, and all transaction figures reflect pre-split terms. The corporate alignment reinforced Predictive Oncology’s broader strategic transition.
